Neural Plasticity / 2016 / Article / Tab 1

Review Article

The Endocannabinoid System as a Therapeutic Target in Glaucoma

Table 1

Studies investigating cannabinoid-mediated neuroprotection in models of glaucoma.

DrugDeliveryStudyModelNeuroprotective effect versus vehicle
(treatment versus control)

THCIPCrandall et al., 2007 [68]Episcleral vein cauterization~20–40% increase (10–20% loss)
THCIVEl-Remessy et al., 2003 [69]Intravitreal NMDA~9% of vehicle
CBDIVEl-Remessy et al., 2003 [69]Intravitreal NMDA~4% of vehicle
WIN 55,212-2TopicalPinar-Sueiro et al., 2013 [70] Ischemia-reperfusion (high IOP)9.88% increase (2.45% loss)
MetAEAIVitNucci et al., 2007 [44]Ischemia-reperfusion (high IOP)18.6% increase (9.4% loss)
URB597IPNucci et al., 2007 [44]Ischemia-reperfusion (high IOP)15.1% increase (12.9% loss)
URB597IPSlusar et al., 2013 [71]Axotomy1 week, 19.5% increase (27.9% loss)
2 weeks, 22.7% increase (58.9% loss)
CelecoxibIPSakai et al., 2009 [72]Ischemia-reperfusion (high IOP)25.8% increase (39.1% loss)
SC-58236IPJu et al., 2003 [45]Ischemia-reperfusion (high IOP)Central, 28.4% increase (27.3% loss)
Peripheral, 28% increase (26.8% loss)

IP, intraperitoneal; IV, intravenous; IVit, intravitreal; study reported quantification of tunnel positive cells only.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.